Tạp chí Tim mạch học Việt Nam

Article detail

Article detail description

Home
BÀI TỔNG QUAN Issue: Số 107S BỆNH MẠCH VÀNH

Assessment of coronary physiology: past, present and future

Phạm Lê Minh: Trường Đại học Y Hà Nội; Hoàng Kim Quân: Viện Tim mạch Việt Nam, Bệnh viện Bạch Mai; Phan Tuấn Đạt: Viện Tim mạch Việt Nam, Bệnh viện Bạch Mai; Mai Trung Anh: Viện Tim mạch Việt Nam, Bệnh viện Bạch Mai; Phạm Mạnh Hùng: Trường Đại học Y Hà Nội;
Published: January 20, 2024
Views: 7

Abstract

The presence of myocardial ischemia is an important prognostic factor in patients with ischemic heart disease. Fractional flow reserve (FFR) and hyperemia-free indexes are used as invasive methods to detect and identify the ischemia-causing coronary disease. Several randomized trials and large registries proved the benefit of measuring physiologic-indexes in patients with coronary artery disease. In addition, recent development ofimaging and computational technologies has enabled image-based physiologic assessment and integration of imaging and physiologic information from invasive and non-invasive assessment data. In this manuscript, we review the history and current status of coronary physiologic assessment and its future perspectives.

Keywords
Myocardial fractional flow reserve Coronary artery disease Atherosclerotic Plaque Nicorandil Intravascular ultrasonography Percutaneous coronary intervention Prognosis

References

1.
Gould KL, Lipscomb K, Hamilton GW. Physiologic basis for assessing critical coronary stenosis. Instantaneous flow response and regional distribution during coronary hyperemia as measures of coronary flow reserve. Am J Cardiol 1974;33(1):87-94.
2.
Anderson HV, Roubin GS, Leimgruber PP, Cox WR, Douglas JS Jr, King SB 3rd, et al. Measurement of transstenotic pressure gradient during percutaneous transluminal coronary angioplasty. Circulation 1986;73(6):1223-30.
3.
Leimgruber PP, Roubin GS, Hollman J, Cotsonis GA, Meier B, Douglas JS, et al. Restenosis after successful coronary angioplasty in patients with single-vessel disease. Circulation 1986;73(4):710-7.
4.
Redd DC, Roubin GS, Leimgruber PP, Abi-Mansour P, Douglas JS Jr, King SB 3rd. The transstenotic pressure gradient trend as a predictor of acute complications after percutaneous transluminal coronary angioplasty. Circulation 1987;76(4):792-801.
5.
De Bruyne B, Pijls NH, Paulus WJ, Vantrimpont PJ, Sys SU, Heyndrickx GR. Transstenotic coronary pressure gradient measurement in humans: in vitro and in vivo evaluation of a new pressure monitoring angioplasty guide wire. J Am Coll Cardiol 1993;22(1):119-26.
6.
Pijls NH, De Bruyne B, Peels K, Van Der Voort PH, Bonnier HJ, Bartunek J, Koolen JJ, et al. Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses. N Engl J Med 1996;334(26):1703-8.
7.
Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van 't Veer M, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 2009;360(3):213-24.
8.
Engstrøm T, Kelbæk H, Helqvist S, Høfsten DE, Kløvgaard L, Holmvang L, et al. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial. Lancet 2015;386(9994):665-71.
9.
Bibas L, Thanassoulis G. Fractional flow reserve–guided multivessel angioplasty in myocardial infarction. N Engl J Med 2017;377(4):396-7.
10.
De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med 2012;367(11):991-1001.
11.
van Nunen LX, Zimmermann FM, Tonino PA, Barbato E, Baumbach A, Engstrøm T, et al. Fractional flow reserve versus angiography for guidance of PCI in patients with multivessel coronary artery disease (FAME): 5-year follow-up of a randomised controlled trial. Lancet 2015;386(10006):1853-60.
12.
Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. The Task Force on myocardial revascularization of the European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS). G Ital Cardiol (Rome) 2019;20(7-8 Suppl 1):1S-61S.
13.
Fearon WF, Shilane D, Pijls NH, Boothroyd DB, Tonino PA, Barbato E, et al. Cost-effectiveness of percutaneous coronary intervention in patients with stable coronary artery disease and abnormal fractional flow reserve. Circulation 2013;128(12):1335-40.
14.
Pijls NH, van Schaardenburgh P, Manoharan G, Boersma E, Bech JW, van 't Veer M, et al. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. J Am Coll Cardiol 2007;49(21):2105-11.
15.
Zimmermann FM, Ferrara A, Johnson NP, van Nunen LX, Escaned J, Albertsson P, et al. Deferral vs. performance of percutaneous coronary intervention of functionally non-significant coronary stenosis: 15-year follow-up of the DEFER trial. Eur Heart J 2015;36(45):3182-8.
Assessment of coronary physiology: past, present and future

Files

PDF
Article Views7
Document Views0
Downloads0
Section BÀI TỔNG QUAN
Issue Số 107S
Category BỆNH MẠCH VÀNH
Pages 121-130
Copyright Holder 2024 Tạp chí Tim mạch học Việt Nam

Related articles section label

Related articles

Related articles category hint

More articles

Study of left ventricular function using tissue-tracking echocardiography in patients with chronic coronary syndrome without indications for coronary revascularization

Objectives: To evaluate the index of global left ventricular longitudinal strain (GLS) and its relationship with some clinical and paraclinical parameters in patients with chronic coronary artery syndrome without indicat...

Chi tiết bài báo
PDF
DOI: 10.58354/jvc.111.2024.866
280
Mai Thị Thương; Nguyễn Văn Thành; Đỗ Doãn Lợi

Frequency and characteristics of Aspirin and Clopidogrel resistance using the VerifyNow test in patients undergoing percutaneous coronary intervention: a cross-sectional, single-center study

Overview: Personalized treatment in cardiovascular diseases is an inevitable trend in practice. The VerifyNow test for assessing aspirin and clopidogrel response is a promising tool in terms of effectiveness and high ava...

Chi tiết bài báo
PDF
DOI: 10.58354/jvc.111.2024.834
286
Vũ Hoàng Vũ; Nguyễn Dương Khang; Võ Thị Diễm Thúy; Trương Quang Bình